CV Sciences has spent the last 12 months in free fall.
The company's Q3 2019 earnings results confirmed many fears selling shareholders would have had.
The pharmaceuticals division is a dud and needs to be divested.
Less than one year ago CV Sciences (OTCQB:CVSI) was trading at $6.25. The company, like Charlotte's Webb and Elixinol, the other companies in its space, were riding high on elevated valuations as investors